Dom Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 24-06-2024
- Paid Up Capital ₹ 0.10 M
as on 24-06-2024
- Company Age 10 Year, 10 Months
- Last Filing with ROC 31 Mar 2021
- Revenue -53.10%
(FY 2020)
- Profit 61.06%
(FY 2020)
- Ebitda 61.35%
(FY 2020)
- Net Worth -28.89%
(FY 2020)
- Total Assets -52.53%
(FY 2020)
About Dom Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Kunal Domadia and Arvindbhai Domadia serve as directors at the Company.
- CIN/LLPIN
U24100GJ2014PTC078548
- Company No.
078548
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 Jan 2014
- Date of AGM
24 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Dom Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kunal Domadia  | Director | 31-Jan-2014 | Current |
| Arvindbhai Domadia | Director | 31-May-2014 | Current |
Financial Performance of Dom Pharma.
Dom Pharma Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 53.1% decrease. The company also saw a substantial improvement in profitability, with a 61.06% increase in profit. The company's net worth observed a substantial decline by a decrease of 28.89%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dom Pharma?
In 2020, Dom Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Kunal Structure (India) Private LimitedActive 18 years 8 monthsKunal Domadia and Arvindbhai Domadia are mutual person
Kunal Bsbk Joint Venture Private LimitedActive 8 years 11 monthsKunal Domadia and Arvindbhai Domadia are mutual person
Garnet Suppliers LlpActive 11 years 10 monthsKunal Domadia and Arvindbhai Domadia are mutual person
- Shantamrut Infrastructure Private LimitedActive 16 years 5 months
Kunal Domadia and Arvindbhai Domadia are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Dom Pharma?
Dom Pharma has a workforce of 4 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dom Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dom Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
